Kindeva Drug Delivery has entered into a definitive agreement to acquire iPharma Labs, Inc. located in San Francisco’s Bay Area. This acquisition will combine iPharma’s expertise and track record in inhalation formulation and development of liquid, dry powder and propellant-based therapies with Kindeva’s expertise in developing, commercializing and manufacturing inhaled therapies. The entire team at iPharma will join Kindeva at closing and will continue to operate from their existing location. The transaction is anticipated to close in the first half of 2022.